FGFR2 and cholangiocarcinoma: Targeted therapies, designed to modulate factors like abhorrent FGFR2 and isocitrate dehydrogenase (IDH), have demonstrated moderate therapeutic responses and survival prolongations in CCA [40,41,42], but further improvements are still needed.